denileukin diftitox
LIGAND-L4389-MR-9901
Phase 2 mab completed
Quick answer
denileukin diftitox for Drug/Agent Toxicity by Tissue/Organ is a Phase 2 program (mab) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LIGAND PHARMACEUTICALS INC
- Indication
- Drug/Agent Toxicity by Tissue/Organ
- Phase
- Phase 2
- Modality
- mab
- Status
- completed